leisure time -WSS

leisure time

author：entertainment 2025-10-01 01:51:17 - browse：35829

Dr. Peter Bach — Peter Bach, shown at the 2019 STAT summit, is now chief medical officer of Delfi. Emilie Pickering for STAT

Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect cancer, said on Monday that it is launching a new test, FirstLook Lung, to try to identify people who could most benefit from lung cancer screening.

The approach represents a new one in the field of liquid biopsy, in which DNA fragments in blood are used to detect or learn about tumors. Grail, another company developing a blood test for cancer screening, has insisted that its product would be best used to detect multiple cancers at once. Other companies, including Exact Sciences and Freenome, are developing tests that would focus on detecting colorectal cancer. But Delfi appears to be the first to focus first on lung cancer, the leading cause of cancer death.

Delfi’s executives, in an interview with STAT, were clear that they view the initial launch as an opportunity to gather information, and not a real commercial coming out. The test will likely become available in limited ways with specific partners and will not initially be covered by insurance. Delfi declined to reveal a specific price, but said that its early access customers, which it is not yet disclosing, will be able to use FirstLook Lung for several hundred dollars. Such a rollout does not require approval from the Food and Drug Administration, which Delfi does not have.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： New documents shed light on MD Anderson Cancer Institute feud

hotspot

WSS

Obesity drugs seen as possible treatment for liver disease MASH

MD Anderson's Padmanee Sharma responds to research credit suit

Surprise medical billing ban raises prices elsewhere

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

focus

leisure time

leisure time

Hollywood unions extend contract negotiations for actors

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Moonlake's readout produced a cash windfall. Risks remain

MD Anderson's Padmanee Sharma responds to research credit suit

Supreme Court strikes down use of affirmative action

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

United colonoscopy coverage change 'may cost lives,' doctors say

FDA warns medical device makers about rise in fabricated data

BioMarin wins approval for gene therapy to treat hemophilia A

Elevance, SCAN deals highlight health insurer acquisition scrutiny

leisure time

Medicare Advantage enrollment hits roughly 33.4 million

PBM reform efforts get punted in Congress

WATCH: Why do our ears pop?

He's a Nobel laureate. Critics say he was misleading on Covid

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

6 phony surgeries that take placebo to the extreme

focus

hotspot

Wikipedia

leisure time